Stifel Maintains Buy on Oruka Therapeutics, Raises Price Target to $72

Benzinga Newsdesk www.benzinga.com Positive 78.4%

Neg 0% Neu 0% Pos 78.4%

Stifel analyst Alex Thompson maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $47 to $72.